Systems-Level Multi-Omics Analysis Resolves the Mechanism of Action of a Novel Multifunctional Nanosystem Against Triple-Negative Breast Cancer
Abstract
1. Introduction
2. Materials and Methods
2.1. Synthesis and Physicochemical Characterization of Ag@MSN-Tf-SeNPs
2.2. Cell Culture
2.3. Quantitative Proteomics
2.4. Quantitative Shotgun Lipidomics
2.5. Targeted Metabolomics Analysis
2.6. Senescence Assay
2.7. Galectin-3 Puncta Assay
3. Results
3.1. SILAC-Based Quantitative Proteomics Reveals Molecular Targets Altered After Ag@MSN-Tf-SeNPs Exposure
3.2. Quantitative Shotgun Lipidomics Complements the Characterization of Biomolecular Alterations Induced by Ag@MSN-Tf-SeNPs Exposure
3.3. Targeted LC–MS/MS Metabolomics Reveals Alterations in Bioenergetic and Central Metabolic Pathways
3.4. Senescence-Associated β-Galactosidase Activity Induced by Ag@MSN-Tf-SeNPs
3.5. Galectin-3 Puncta Formation Indicates Lysosomal Damage Induced by Ag@MSN-Tf-SeNPs
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Freihat, O.; Sipos, D.; Kovacs, A. Global burden and projections of breast cancer incidence and mortality to 2050: A comprehensive analysis of GLOBOCAN data. Front. Public Health 2025, 13, 1622954. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sood, D.; Kaur, C.; Kumar, N.; Kumar, R.; Singh, G. Triple-negative breast cancer: Challenges, advances, and promising therapeutic interventions. Med. Oncol. 2025, 42, 506. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Montalvo-Quiros, S.; Aragoneses-Cazorla, G.; Garcia-Alcalde, L.; Vallet-Regi, M.; Gonzalez, B.; Luque-Garcia, J.L. Cancer cell targeting and therapeutic delivery of silver nanoparticles by mesoporous silica nanocarriers: Insights into the action mechanisms using quantitative proteomics. Nanoscale 2019, 11, 4531–4545. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xiong, X.; Zheng, L.W.; Ding, Y.; Chen, Y.F.; Cai, Y.W.; Wang, L.P.; Huang, L.; Liu, C.C.; Shao, Z.M.; Yu, K.D. Breast cancer: Pathogenesis and treatments. Singal. Transduct. Target. Ther. 2025, 10, 49. [Google Scholar] [CrossRef] [Scilit]
- Samad, M.A.; Ahmad, I.; Zughaibi, T.A.; Suhail, M.; Zaidi, S.K.; Al-Abbasi, F.A.; Tabrez, S. Nanotechnology-based drug delivery for breast cancer treatment: Current applications and future directions. Eur. J. Med. Chem. Rep. 2025, 14, 100268. [Google Scholar] [CrossRef] [Scilit]
- Shahalaei, M.; Azad, A.K.; Sulaiman, W.M.A.W.; Derakhshani, A.; Mofakham, E.B.; Mallandrich, M.; Kumarasamy, V.; Subramaniyan, V. A review of metallic nanoparticles: Present issues and prospects focused on the preparation methods, characterization techniques, and their theranostic applications. Front. Chem. 2024, 12, 1398979. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Machuca, A.; Garcia-Calvo, E.; Anunciacao, D.S.; Luque-Garcia, J.L. Rhodium nanoparticles as a novel photosensitizing agent in photodynamic therapy against cancer. Chem. Eur. J. 2020, 26, 7685–7691. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Aragoneses-Cazorla, G.; Buendia-Nacarino, M.P.; Mena, M.L.; Luque-Garcia, J.L. A multi-omics approach to evaluate the toxicity mechanisms associated with silver nanoparticles exposure. Nanomaterials 2022, 12, 1762. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Swanner, J.; Fahrenholtz, C.D.; Tenvooren, I.; Bernish, B.W.; Sears, J.J.; Hooker, A.; Furdui, C.M.; Alli, E.; Li, W.; Donati, G.L.; et al. Silver nanoparticles selectively treat triple-negative breast cancer cells without affecting non-malignant breast epithelial cells in vitro and in vivo. FASEB BioAdv. 2019, 1, 639–660. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Okur, E.E.; Akdaşçi, E.; Eker, F.; Bechelany, M.; Karav, S. Silver nanoparticles as anticancer agents: Mechanisms insight, current studies, and limitations. Pharmaceuticals 2026, 19, 241. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Aragoneses-Cazorla, G.; Vallet-Regi, M.; Gomez-Gomez, M.M.; Gonzalez, B.; Luque-Garcia, J.L. Integrated transcriptomics and metabolomics analysis reveals the biomolecular mechanisms associated to the antitumoral potential of a novel silver-based core@shell nanosystem. Microchim. Acta 2023, 190, 132. [Google Scholar] [CrossRef] [Scilit]
- Estevez, H.; Garcia-Calvo, E.; Alvarez-Fernandez Garcia, R.; Sanchez-Diaz, R.; Lazcano, J.J.; Martin, P.; Luque-Garcia, J.L. SILAC-based nuclear proteomics uncovers antitumor mechanisms of selenium nanoparticles with in vivo validation in a melanoma model. J. Drug Deliv. Sci. Tech. 2025, 111, 107155. [Google Scholar] [CrossRef] [Scilit]
- Estevez, H.; Garcia-Calvo, E.; Rivera-Torres, J.; Vallet-Regi, M.; Gonzalez, B.; Luque-Garcia, J.L. Transcriptome analysis identifies novel mechanisms associated with the antitumor effect of chitosan-stabilized selenium nanoparticles. Pharmaceutics 2021, 13, 356. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Anjum, S.; Hashim, M.; Imran, M.; Babur, S.; Adnan, S.; Hano, C.; Ibrahim, W.N. Selenium nanoparticles in cancer therapy: Unveiling cytotoxic mechanisms and therapeutic potential. Cancer Rep. 2025, 8, e70210. [Google Scholar] [CrossRef] [Scilit]
- Yousefiasl, S.; Ghovvati, M.; Alibakhshi, A.; Azizi, M.; Samadi, P.; Kumar, A.; Shojaeian, A.; Sharifi, E.; Zare, E.N.; Dey, A.D.; et al. Smart mesoporous silica nanoparticles in cancer: Diagnosis, treatment, immunogenicity, and clinical Translation. Small 2025, 21, 2408898. [Google Scholar] [CrossRef] [Scilit]
- Machuca, A.; Alvarez-Fernandez Garcia, R.; Garcia-Garcia, A.; Aragoneses-Cazorla, G.; Castillo-Lluva, S.; Vallet-Regi, M.; Gonzalez, B.; Garcia-Calvo, E.; Luque-Garcia, J.L. A third-generation rhodium-based nanophotosensitizer for precision photodynamic cancer therapy. J. Colloid Interface Sci. 2026, 713, 140143. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Meng, J.; Wang, Z.G.; Zhao, X.; Wang, Y.; Chen, D.Y.; Liu, D.L.; Ji, C.C.; Wang, T.F.; Zhang, L.M.; Bai, H.X.; et al. Silica nanoparticle design for colorectal cancer treatment: Recent progress and clinical potential. World J. Clin. Oncol. 2024, 15, 667–673. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Aragoneses-Cazorla, G.; Serrano-Lopez, J.; Martinez-Alfonzo, I.; Vallet-Regi, M.; Gonzalez, B.; Luque-Garcia, J.L. A novel hemocompatible core@shell nanosystem for selective targeting and apoptosis induction in cancer cells. Inorg. Chem. Front. 2021, 8, 2697–2712. [Google Scholar] [CrossRef] [Scilit]
- He, X.; Chen, F.; Chang, Z.; Waqar, K.; Hu, H.; Zheng, X.; Wang, Y.; Dong, W.; Yang, C. Silver mesoporous silica nanoparticles: Fabrication to combination therapies for cancer and infection. Chem. Rec. 2022, 22, e202100287. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Volcanes Moreno, V.; Yohai, L.; Procaccini, R.; Pellice, S. Silver-functionalized mesoporous silica nanoparticle coatings: Optimal thermal stability and ionic activity for antimicrobial applications. Colloids Surf. A Physicochem. Eng. Asp. 2025, 711, 136387. [Google Scholar] [CrossRef] [Scilit]
- Buendia-Nacarino, M.P.; Alvarez-Fernandez Garcia, R.; Martinez-lopez, A.; Castillo-lluva, S.; Gonzalez, B.; Luque-Garcia, J.L. Silver-selenium hybrid nanocomposite with combined cytotoxic and metabolic reprogramming effects in triple-negative breast cancer. Colloids Surf. B Biointerfaces 2026, 263, 115613. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Machuca, A.; Garcia-Calvo, E.; Anunciacao, D.S.; Luque-Garcia, J.L. Integration of transcriptomics and metabolomics to reveal the molecular mechanisms underlying rhodium nanoparticles-based photodynamic cancer therapy. Pharmaceutics 2021, 13, 1629. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Abdelkader, Y.; Perez-Davalos, L.; LeDuc, R.; Zahedi, R.P.; Labouta, H.I. Omics approaches for the assessment of biological responses to nanoparticles. Adv. Drug Deliv. Rev. 2023, 200, 114992. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yan, L.; Duan, B.; Wang, T.; Wang, T.; Chi, H.; Gao, H. Omics-enhanced nanomedicine: Integrating multi-omics for precision cancer diagnosis and therapy. Discov. Oncol. 2026, 17, 97. [Google Scholar]
- Wang, Z.; Zhang, T.; Tang, M. Navigating nanotoxicity: Unravelling nanomaterial-induced effects via multi-omics integration. NanoImpact 2025, 38, 100565. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nielsen, I.O.; Olsen, A.V.; Dicroce-Giacobini, J.; Papaleo, E.; Andersen, K.K.; Jäättelä, M.; Maeda, K.; Bilgin, M. Comprehensive evaluation of a quantitative shotgun lipidomics platform for mammalian sample analysis on a high-resolution mass spectrometer. J. Am. Soc. Mass. Spec. 2020, 31, 894–907. [Google Scholar] [CrossRef] [Scilit]
- Aits, S.; Kricker, J.; Liu, B.; Ellegaard, A.M.; Hämälistö, S.; Tvingsholm, S.; Corcelle-Termeau, E.; Hogh, S.; Farkas, T.; Jonassen, A.H.; et al. Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin punctual assay. Autophagy 2015, 11, 1408–1424. [Google Scholar] [PubMed]
- Brown, D.T.; Alexander, B.T.; Sittman, D.B. Differential effect of H1 variant overexpression on cell cycle progression and gene expression. Nucleic Acids Res. 1996, 24, 486–493. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xu, J.; Li, Z.; Zuo, X.; Li, G.; Zhang, X.; Zhang, B.; Cui, Y. Knockdown of NAA25 suppresses breast cancer progression by regulating apoptosis and cell cycle. Front. Oncol. 2022, 11, 755267. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Thompson, M.W.; Hershj, L.B. The puromycin-sensitive aminopeptidase proliferative disorders. In Aminopeptidases in Biology and Disease; Hooper, N.M., Lendeckel, Y., Eds.; Proteases in Biology and Disease; Springer: Boston, MA, USA, 2004; Volume 2. [Google Scholar]
- Ito, E.; Yue, S.; Moriyama, E.H.; Hui, A.B.; Kim, I.; Shi, W.; Alajez, N.M.; Bhogal, N.; Li, G.H.; Datti, A.; et al. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci. Transl. Med. 2011, 3, 3001922. [Google Scholar] [CrossRef] [Scilit]
- Zhu, Y.; He, S.; Wang, Z.; Xi, H.; Lu, W.; Lin, X. Predictive and clinicopathological importance of HMGB2 in various carcinomas: A meta and bioinformatic approach. Sci. Rep. 2025, 15, 11003. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Shao, C.; Wang, R.; Kong, D.; Gao, Q.; Xu, C. Identification of potential core genes in gastric cancer using bioinformatics analysis. J. Gastrointest. Oncol. 2021, 12, 2109–2122. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wajapeyee, N.; Beamon, T.C.; Gupta, R. Roles and therapeutic targeting of ceramide metabolism in cancer. Mol. Metab. 2024, 83, 101936. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Du, R.; Liu, B.; Zhou, L.; Wang, D.; He, X.; Xu, X.; Zhang, L.; Niu, C.; Liu, S. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer. Cell Death Dis. 2018, 9, 126. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lin, P.; Mobasher, M.E.; Hakakian, Y.; Kakarla, V.; Naseem, A.F.; Ziai, H.; Alawi, F. Differential requirements for H/ACA ribonucleoprotein components in cell proliferation and response to DNA damage. Histochem. Cell Biol. 2015, 144, 543–558. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cha, Y.; Kim, D.K.; Hyun, J.; Kim, S.J.; Park, K.S. TCEA3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells. Cell. Signal. 2013, 25, 1245–1251. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Paizula, X.; Wulaying, A.; Chen, D.; Ou, J. KHSRP has oncogenic functions and regulates the expression and alternative splicing of DNA repair genes in breast cancer MDA-MB-231 cells. Sci. Rep. 2024, 14, 14694. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Robichaud, N.; Sonenberg, N. Translational control and the cancer cell response to stress. Curr. Opin. Cell Biol. 2017, 45, 102–109. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Oakes, S.A. Endoplasmic reticulum stress signaling in cancer cells. Am. J. Pathol. 2020, 190, 934–946. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, J.; Lee, J.; Liem, D.; Ping, P. HSPA5 Gene encoding Hsp70 chaperone BiP in the endoplasmic reticulum. Gene 2017, 618, 14–23. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rehati, A.; Abuduaini, B.; Liang, Z.; Chen, D.; He, F. Identification of heat shock protein family A member 5 (HSPA5) targets involved in nonalcoholic fatty liver disease. Genes Immun. 2023, 24, 124–129. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Duxfield, A.; Munkley, J.; Briggs, M.D.; Dennis, E.P. CRELD2 is a novel modulator of calcium release and calcineurin-NFAT signalling during osteoclast differentiation. Sci. Rep. 2022, 12, 13884. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sun, L.; Wu, S.; Wang, H.; Zhang, T.; Zhang, M.; Bai, X.; Zhang, X.; Li, B.; Zhang, C.; Li, Y.; et al. PDCD6 regulates lactate metabolism to modulate LC3-associated phagocytosis and antibacterial defense. Nat. Commun. 2024, 15, 10157. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cai, R.; Wang, P.; Zhao, X.; Lu, X.; Deng, R.; Wang, X.; Hong, C.; Lin, J. Reticulocalbin3: A Ca2+ homeostasis regulator that promotes esophageal squamous cell carcinoma progression and cisplatin resistance. Cancer Sci. 2022, 113, 3593–3607. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Li, Y.; Huang, J.; Zeng, B.; Yang, D.; Sun, J.; Yin, X.; Lu, M.; Qiu, Z.; Peng, W.; Xiang, T.; et al. PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation. Cancer Lett. 2018, 430, 109–122. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chen, F.; Liang, R.R.; Zhang, J.; Kang, R.; Tang, D.; Liu, J. CYP51A1 in health and disease: From sterol metabolism to regulated cell death. Cell Death Discov. 2025, 11, 322. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Vock, C.; Nitz, I.; Döing, F. Transcriptom-based identification of a putative role for the human acyl-CoA-binding-protein (ACBP) in vesicular trafficking. Cell. Mol. Biol. 2010, 56, 1261–1265. [Google Scholar]
- Cao, R.; Zhang, Z.; Tian, C.; Sheng, W.W.; Dong, Q.; Dong, M. Down-regulation of MSMO1 promotes the development and progression of pancreatic cancer. J. Cancer 2022, 13, 3013–3021. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Long, T.; Hassan, A.; Thompson, B.M.; McDonald, J.G.; Wang, J.; Li, X. Structural basis for human sterol isomerase in cholesterol biosynthesis and multidrug recognition. Nat. Commun. 2019, 10, 2452. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zeng, C.; Riad, A.; Mach, R.H. The biological function of sigma-2 receptor/tmem97 and its utility in pet imaging studies in cancer. Cancers 2020, 12, 1877. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Castellano, B.M.; Thelen, A.M.; Moldavski, O.; Feltes, M.K.; van der Welle, R.E.N.; Mydock-McGrane, L.; Jiang, X.; van Eijkeren, R.J.; Davis, O.B.; Louie, S.M.; et al. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann pick C1 signaling complex. Science 2018, 355, 1306–1311. [Google Scholar]
- Krasniak, C.S.; Ahmad, S.T. The role of CHMP2BIntron5 in autophagy and frontotemporal dementia. Brain Res. 2016, 176, 151–157. [Google Scholar] [CrossRef] [Scilit]
- Yu, T.; Cheng, W.; Zhang, J.; Wang, T.; Liu, Y.; Duan, Y.; Hu, A.; Feng, J.; Li, M.; Li, Y.; et al. Identification of a PANoptosis-related gene signature for predicting the prognosis, tumor microenvironment and therapy response in breast cancer. J. Cancer 2024, 15, 428–443. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yang, Y.; Wang, Q.; Song, D.; Zen, R.; Zhang, L.; Wang, Y.; Yang, H.; Zhang, D.; Jia, J.; Zhang, J.; et al. Lysosomal dysfunction and autophagy blockade contribute to autophagy-related cancer suppressing peptide-induced. J. Exp. Clin. Cancer Res. 2020, 39, 197. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tiedemann, K.; Sadvakassova, G.; Mikolajewicz, N.; Juhas, M.; Sabirova, Z.; Tabariès, S.; Gettemans, J.; Siegel, P.M.; Komarova, S.V. Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 2019, 12, 462–474. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fusella, F.; Seclì, L.; Busso, E.; Krepelova, A.; Moiso, E.; Rocca, S.; Conti, L.; Annaratone, L.; Rubinetto, C.; Mello-Grand, M.; et al. The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis. Nat. Commun. 2017, 8, 1636. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nakano, S.; Nishikawa, M.; Kobayashi, T.; Harlin, E.W.; Ito, T.; Sato, K.; Sugiyama, T.; Yamakawa, H.; Nagase, T.; Ueda, H. The Rho guanine nucleotide exchange factor PLEKHG1 is activated by interaction with and phosphorylation by Src family kinase member FYN. J. Biol. Chem. 2022, 298, 101579. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cayado-Gutiérrez, N.; Moncalero, V.L.; Rosales, E.M.; Berón, W.; Salvatierra, E.E.; Alvarez-Olmedo, D.; Radrizzani, M.; Ciocca, D.R. Downregulation of Hsp27 (HSPB1) in MCF-7 human breast cancer cells induces upregulation of PTEN. Cell Stress Chaperones 2013, 18, 243–249. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Youn, C.K.; Lee, J.H.; Hariharasudhan, G.; Kim, H.B.; Kim, J.; Lee, S.; Lim, S.C.; Yoon, S.P.; Park, S.G.; Chang, I.Y.; et al. HspBP1 is a dual function regulatory protein that controls both DNA repair and apoptosis in breast cancer cells. Cell Death Dis. 2022, 13, 309. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Deng, N.; Zhang, X.; Zhang, Y. BAIAP2L1 accelerates breast cancer progression and chemoresistance by activating AKT signaling through binding with ribosomal protein L3. Cancer Sci. 2023, 114, 764–780. [Google Scholar] [PubMed]
- Rajput, S.; Ma, C.X. Beyond genomics: Biologic insights from the CPTAC proteogenomic analysis of breast cancer. Transl. Cancer Res. 2016, 5, S713–S715. [Google Scholar] [CrossRef] [Scilit]
- Li, L.; Yang, X.; He, M.; Xu, X.; Xuan, X.; Zhang, J.; Zhang, L.; Xu, H.; Li, D. The expression and clinical significance of STAMBP in breast cancer. Mol. Biol. Rep. 2023, 50, 899–906. [Google Scholar] [PubMed]
- Wang, J.; Yuan, T.; Yang, B.; He, Q.; Zhu, H. SDH defective cancers: Molecular mechanisms and treatment strategies. Cell Biol. Toxicol. 2025, 41, 74. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Santidrian, A.F.; Matsuno-Yagi, A.; Ritland, M.; Seo, B.B.; LeBoeuf, S.E.; Gay, L.J.; Yagi, T.; Felding-Habermann, B. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J. Clin. Investig. 2013, 123, 1068–1081. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, C.; Zhou, D.; Yang, K.; Xu, N.; Peng, J.; Zhu, Z. Research progress on the pathogenesis of the SDHB mutation and related diseases. Biomed. Pharmacother. 2023, 167, 115500. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, B.; Liu, Z.H.; Li, J.J.; Xu, J.X.; Guo, Y.M.; Zhang, J.X.; Chu, T.; Feng, Z.F.; Jiang, Q.Y. Role of ferroptosis in breast cancer: Molecular mechanisms and therapeutic interventions. Cell Signal 2025, 134, 111869. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lee, S.Y.; Kim, S.; Song, Y.; Kim, N.; No, J.; Kim, K.M.; Seo, H.R. Sorbitol dehydrogenase induction of cancer cell necroptosis and macrophage polarization in the HCC microenvironment suppresses tumor progression. Cancer Lett. 2022, 551, 215960. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhou, W.; Tang, Z.; Li, Y.; Lu, L.; Bi, T.; Zhan, L. Hippocampal PDHA1 gene knockout inhibits the Warburg effect leading to cognitive dysfunction and attenuates the beneficial effects of ZiBuPiYin recipe on cognition. J. Ethnopharmacol. 2025, 337, 118895. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wagner, F.; Kunz, T.C.; Chowdhury, S.R.; Thiede, B.; Fraunholz, M.; Eger, D.; Kozjak-Pavlovic, V. Armadillo repeat-containing protein 1 is a dual localization protein associated with mitochondrial intermembrane space bridging complex. PLoS ONE 2019, 14, e0218303. [Google Scholar] [CrossRef] [Scilit] [PubMed]






| Common Name | Accession | Protein Name | SILAC Ratio (Log) | RSD | Mascot Score |
|---|---|---|---|---|---|
| CRELD2 | Q6UXH1 | Protein disulfide isomerase CRELD2 | −0.73 | 0 | 31 |
| KRAS | P01116 | GTPase Kras | −0.68 | 0 | 43 |
| AIMP1 | Q12904 | Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 | −0.64 | 0 | 52 |
| EHD2 | Q9NZN4 | EH domain-containing protein 2 | −0.52 | 0 | 30 |
| ARMC1 | Q9NVT9 | Armadillo repeat-containing protein 1 | −0.52 | 9.61 | 20 |
| STXBP2 | Q15833 | Syntaxin-binding protein 2 | −0.46 | 0 | 30 |
| CCNB1 | P14635 | G2/mitotic-specific cyclin-B1 | −0.43 | 26.54 | 36 |
| NAA25 | Q14CX7 | N-alpha-acetyltransferase 25, NatB auxiliary subunit | −0.41 | 0 | 28 |
| HMGCS1 | Q01581 | Hydroxymethylglutaryl-CoA synthase, cytoplasmic | −0.38 | 12.6 | 21 |
| NOC4L | Q9BVI4 | Nucleolar complex protein 4 homolog | −0.34 | 0 | 18 |
| CYP51A1 | Q16850 | Lanosterol 14-alpha demethylase | −0.34 | 17.48 | 90 |
| ARHGEF1 | Q92888 | Rho guanine nucleotide exchange factor 1 | −0.33 | 27.74 | 20 |
| LCP1 | P13796 | Plastin-2 | −0.29 | 24.17 | 1080 |
| MAP1LC3A | Q9H492 | Microtubule-associated proteins 1A/1B light chain 3A | −0.29 | 9.2 | 86 |
| MSMO1 | Q15800 | Methylsterol monooxygenase 1 | −0.29 | 21.8 | 107 |
| UROD | P06132 | Uroporphyrinogen decarboxylase | −0.28 | 28.87 | 146 |
| CHMP2B | Q9UQN3 | Charged multivesicular body protein 2b | −0.27 | 0.47 | 16 |
| NPEPPSL1 | A6NEC2 | Puromycin-sensitive aminopeptidase-like protein | −0.27 | 0 | 18 |
| EIF2S1 | P05198 | Eukaryotic translation initiation factor 2 subunit 1 | −0.26 | 13.51 | 68 |
| MANF | P55145 | Mesencephalic astrocyte-derived neurotrophic factor | −0.24 | 3.4 | 244 |
| HSPA5 | P11021 | Endoplasmic reticulum chaperone BiP | −0.24 | 22.38 | 989 |
| TFRC | P02786 | Transferrin receptor protein 1 | −0.22 | 23 | 25 |
| HM13 | Q8TCT9 | Minor histocompatibility antigen H13 | −0.21 | 21.27 | 243 |
| TMEM97 | Q5BJF2 | Sigma intracellular receptor 2 | −0.19 | 4.19 | 52 |
| ALDOA | P04075 | Fructose-bisphosphate aldolase A | −0.19 | 26.8 | 1563 |
| CHORDC1 | Q9UHD1 | Cysteine and histidine-rich domain-containing protein 1 | −0.18 | 24.87 | 80 |
| H2AC20 | Q16777 | Histone H2A type 2-C | −0.18 | 27.16 | 2172 |
| PSMD2 | Q13200 | 26S proteasome non-ATPase regulatory subunit 2 | −0.17 | 20.07 | 163 |
| RPL24 | P83731 | 60S ribosomal protein L24 | −0.17 | 25.7 | 655 |
| PSMB6 | P28072 | Proteasome subunit beta type-6 | 0.15 | 18.78 | 139 |
| HMGB2 | P26583 | High mobility group protein B2 | 0.16 | 14.81 | 63 |
| ANXA3 | P12429 | Annexin A3 | 0.17 | 21.92 | 1839 |
| NASP | P49321 | Nuclear autoantigenic sperm protein | 0.18 | 29.26 | 109 |
| TCEA1 | P23193 | Transcription elongation factor A protein 1 | 0.18 | 28.89 | 265 |
| GAR1 | Q9NY12 | H/ACA ribonucleoprotein complex subunit 1 | 0.18 | 28.69 | 50 |
| C11orf68 | Q9H3H3 | UPF0696 protein C11orf68 | 0.21 | 5.45 | 30 |
| ABHD10 | Q9NUJ1 | Palmitoyl-protein thioesterase ABHD10, mitochondrial | 0.21 | 9.92 | 126 |
| PDHA1 | P08559 | Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial | 0.21 | 20.29 | 123 |
| BAIAP2 | Q9UQB8 | Brain-specific angiogenesis inhibitor 1-associated protein 2 | 0.21 | 20.28 | 54 |
| GNB4 | Q9HAV0 | Guanine nucleotide-binding protein subunit beta-4 | 0.23 | 15.84 | 151 |
| MTHFD2 | P13995 | Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial | 0.24 | 11.46 | 36 |
| H1-10 | Q92522 | Histone H1.10 | 0.24 | 26.1 | 572 |
| UQCRQ | O14949 | Cytochrome b-c1 complex subunit 8 | 0.25 | 26.95 | 72 |
| TOR1AIP1 | Q5JTV8 | Torsin-1A-interacting protein 1 | 0.27 | 11.54 | 145 |
| EBP | Q15125 | 3-beta-hydroxysteroid-Delta(8), Delta(7)-isomerase | 0.27 | 15.2 | 25 |
| KHSRP | Q92945 | Far upstream element-binding protein 2 | 0.27 | 27.63 | 66 |
| TTC38 | Q5R3I4 | Tetratricopeptide repeat protein 38 | 0.28 | 12.45 | 229 |
| GGH | Q92820 | Gamma-glutamyl hydrolase | 0.28 | 7.35 | 28 |
| HIBADH | P31937 | 3-hydroxyisobutyrate dehydrogenase, mitochondrial | 0.29 | 19.54 | 55 |
| GTF2F1 | P35269 | General transcription factor IIF subunit 1 | 0.3 | 22.89 | 31 |
| RCN3 | Q96D15 | Reticulocalbin-3 | 0.32 | 27.32 | 21 |
| PPT1 | P50897 | Palmitoyl-protein thioesterase 1 | 0.34 | 7.42 | 19 |
| EPS8L2 | Q9H6S3 | Epidermal growth factor receptor kinase substrate 8-like protein 2 | 0.35 | 12.88 | 36 |
| MTX2 | O75431 | Metaxin-2 | 0.35 | 22.57 | 57 |
| HSPBP1 | Q9NZL4 | Hsp70-binding protein 1 | 0.37 | 27.69 | 25 |
| SDHB | P21912 | Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial | 0.38 | 5.96 | 68 |
| HEXB | P07686 | Beta-hexosaminidase subunit beta | 0.39 | 15.84 | 128 |
| CETN3 | O15182 | Centrin-3 | 0.39 | 0 | 17 |
| SERPINE1 | P05121 | Plasminogen activator inhibitor 1 | 0.42 | 3.09 | 17 |
| PEF1 | Q9UBV8 | Peflin | 0.43 | 0 | 16 |
| MIF | P14174 | Macrophage migration inhibitory factor | 0.45 | 13.31 | 106 |
| SCPEP1 | Q9HB40 | Retinoid-inducible serine carboxypeptidase | 0.46 | 19.98 | 58 |
| PDCD6 | O75340 | Programmed cell death protein 6 | 0.48 | 12.34 | 53 |
| CTSZ | Q9UBR2 | Cathepsin Z | 0.52 | 21.44 | 49 |
| ALB | P02768 | Albumin | 0.53 | 10.22 | 97 |
| RPL7 | P18124 | 60S ribosomal protein L7 | 0.54 | 2.61 | 61 |
| SLC7A5 | Q01650 | Large neutral amino acids transporter small subunit 1 | 0.57 | 18.43 | 45 |
| TUFM | P49411 | Elongation factor Tu, mitochondrial | 0.66 | 0 | 20 |
| SORD | Q00796 | Sorbitol dehydrogenase | 0.74 | 0 | 20 |
| ARF5 | P84085 | ADP-ribosylation factor 5 | 1.09 | 0 | 714 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Buendia-Nacarino, M.P.; Bulfon, D.; Tom, N.; Rohde, M.; Bilgin, M.; Jäättelä, M.; Mena, M.L.; Alvarez-Fernandez Garcia, R.; Luque-Garcia, J.L. Systems-Level Multi-Omics Analysis Resolves the Mechanism of Action of a Novel Multifunctional Nanosystem Against Triple-Negative Breast Cancer. Pharmaceutics 2026, 18, 919. https://doi.org/10.3390/pharmaceutics18080919
Buendia-Nacarino MP, Bulfon D, Tom N, Rohde M, Bilgin M, Jäättelä M, Mena ML, Alvarez-Fernandez Garcia R, Luque-Garcia JL. Systems-Level Multi-Omics Analysis Resolves the Mechanism of Action of a Novel Multifunctional Nanosystem Against Triple-Negative Breast Cancer. Pharmaceutics. 2026; 18(8):919. https://doi.org/10.3390/pharmaceutics18080919
Chicago/Turabian StyleBuendia-Nacarino, María Pilar, Dominik Bulfon, Nikola Tom, Mikkel Rohde, Mesut Bilgin, Marja Jäättelä, María Luz Mena, Roberto Alvarez-Fernandez Garcia, and Jose L. Luque-Garcia. 2026. "Systems-Level Multi-Omics Analysis Resolves the Mechanism of Action of a Novel Multifunctional Nanosystem Against Triple-Negative Breast Cancer" Pharmaceutics 18, no. 8: 919. https://doi.org/10.3390/pharmaceutics18080919
APA StyleBuendia-Nacarino, M. P., Bulfon, D., Tom, N., Rohde, M., Bilgin, M., Jäättelä, M., Mena, M. L., Alvarez-Fernandez Garcia, R., & Luque-Garcia, J. L. (2026). Systems-Level Multi-Omics Analysis Resolves the Mechanism of Action of a Novel Multifunctional Nanosystem Against Triple-Negative Breast Cancer. Pharmaceutics, 18(8), 919. https://doi.org/10.3390/pharmaceutics18080919

